Cell Therapy Developer SBioMedics Raises 2 Billion Won in Paid-in Capital Increase... "For Operating Fund Procurement"
Esbiomedics, a KOSDAQ-listed cell therapy developer, announced on the 13th that it has decided to raise 2 billion KRW through a third-party allotment paid-in capital increase to secure operating funds and other expenses.
A total of 271,320 new common shares will be issued at a price of 25,800 KRW per share. The third-party allotment recipients include SYS Holdings (116,280 shares) and Dongkook Pharmaceutical (58,140 shares), among others.
Hot Picks Today
"Don't Say 'Americano' Anymore" After the Uproar... Now a Surge in 'Patriotic Spending' Sweeps Canada
- [Exclusive] "Please Raise Redevelopment and Reconstruction Costs"... 1.6 Trillion Won Cut After Inflated Requests
- "Not Just a Childhood Disease": Woman in Her 40s Dies as Highly Contagious Measles Sparks Alarm in U.S.
- "Looking for the Korean Man Who Sat Beside Me" Japanese Tourist Posts Story of 50,000 Won, Red Ginseng, and Chocolate on Social Media
- "Weight Dropped Rapidly... Anyone Can Get It Easily": Why a Woman in Her 20s Quit Mountzaro After Losing 6kg in a Month
The company stated that the purpose of the third-party allotment capital increase is "to achieve management objectives through operating funds and other funds (clinical trial costs)."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
